Trikafta 100-50-75 MG/75MG PKT 14S
Ended Awarded Last action
- Contract number
- SPE2DR26FQWF9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $57,956
Award facts
- Contract value 100% obligated
- $57,955.65 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $57,955.65 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/75 mg packets in quantities of 14. The delivery order, issued December 12, 2025, with an ultimate completion date of December 15, 2025, carries no set-aside designation and was awarded competitively. This delivery order falls under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion contract awarded November 13, 2025, that authorizes DLA to issue firm fixed-price orders for comprehensive pharmaceutical products and medical consumables to support Department of Defense military healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, demonstrating substantial federal contracting activity through numerous delivery orders issued by the Defense Logistics Agency's Medical Supply Chain division. The company's extensive product portfolio encompasses branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables, positioning it to fulfill the diverse and specialized pharmaceutical requirements of the military medical system. As one of multiple regional prime vendor contractors under the broader PPV-G GEN V acquisition strategy, the company's established performance on delivery orders validates its capability to support recurring medical supply needs across the Department of Defense's global healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FQWF9?
SPE2DR26FQWF9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 12, 2025.
How much is contract SPE2DR26FQWF9 worth?
The government has obligated $57,956 on SPE2DR26FQWF9.
Is contract SPE2DR26FQWF9 an order under another contract?
Yes. SPE2DR26FQWF9 is a delivery order under SPE2DR25D9353, an indefinite delivery contract.
Was contract SPE2DR26FQWF9 competed?
The extent of competition for SPE2DR26FQWF9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award